Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment
Keywords:
finastreide, spironolactone, FPHLAbstract
Introduction: Female pattern hair loss (FPHL) is one of the most common forms of diffuse alopecia in females.. Despite the availability of multiple treatment options, FPHL management poses challenges for the dermatologist.
Objectives: We aimed to compare the efficacy and safety of topical finasteride 1% solution and spironolactone 5% solution to minoxidil 5% solution in the treatment of FPHL clinically and trichoscopically.
Methods: Forty-five adult female patients diagnosed with FPHL were divided into 3 groups of 15 each. Group A was treated with topical finasteride 1%, group B used topical spironolactone 5%, and group C was treated with topical minoxidil solution 5 %, for 16 weeks.
Results: By the end of 16th week, significant improvement in the Sinclair scale was observed in groups A and C, but the difference between the 3 groups was statistically insignificant. Trichoscopically, hair density significantly increased in groups A and C. There was a significant reduction in the number of patients with yellow dots, peripilar sign, as well as single hair follicular units (FU) in group A. In group C, a significant reduction in number of patients with yellow dots and single hair FU was documented. No trichoscopic changes were detected in group B.
Conclusions: Topical finasteride is as safe and effective as topical minoxidil in FPHL. Both treatments showed higher efficacy clinically and trichoscopically than topical spironolactone. The use of topical finasteride may be another solution for the treatment of FPHL in minoxidil non-responders or in the presence of intolerable side effects
References
Penha M, Ramos P, De Souza V, Miot H. Development and Validation of a Dermoscopic Severity Score for Female Pattern Hair Loss. Skin Appendage Disord.2022;8:228–235. DOI: 10.1159/000520108. PMID: 35707288.
Zhang X , Caulloo S, Zhao Y, Zhang B, Cai Z, Yang J. Female pattern hair loss: clinico-laboratory findings and trichoscopy depending on disease severity. Int J Trichology. 2012;4(1):23-8. DOI: 10.4103/0974-7753.96082. PMID: 22628986
Fabbrocini G, Cantelli M, MasaràA, Annunziata M , Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. IJWD.2018;4: 203–211. DOI: 10.1016/j.ijwd.2018.05.001. PMID: 30627618.
Rossi A, ,Magri F, Arino A, et al. Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients.Dermatol Pract Concept.2020;10(2):e2020039. DOI: 10.5826/dpc.1002a39. PMID: 32363101.
Gupta A, Foley K. 5% minoxidil: Treatment for female pattern hair loss. Skin Therapy Lett.2014;19: 5–7. PMID: 25807073.
Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol.2019;20 (1):147–153. DOI: 10.1007/s40257-018-0387-0. PMID: 30206824.
Ammar A ,Elshahid A , Abdel-Dayem H , Mohamed A, Elsaie M. Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study .J Cosmet Dermatol. 2022; 21:5790–5799. DOI: 10.1111/jocd.15328. PMID: 36039391.
Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: Do they play a role? Skin PharmacolPhysiol.2013;26:101–107. DOI: 10.1159/000346698. PMID: 23428658.
Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning.2013
Abdel-Raouf H, Aly U, Medhat W, Ahmed S, Abdel-Aziz R. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021;34(1):e14678. DOI: 10.1111/dth.14678. PMID: 33320406
Shin H, Won C, Lee S, Kwon O, Kim K, Eun H. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss. Am J Clin Dermatol. 2007;8(5):285-290. DOI: 10.2165/00128071-200708050-00003. PMID: 17902730
Ghonemy S, Alarawi A, Bessar H. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatolog Treat. 2021;32(2):236-241. DOI: 10.1080/09546634.2019.1654070. PMID: 31403367.
Suchonwanit P, Srisuwanwattana P, Chalermroj N, KhunkhetS.A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.JEADV.. 2018;32 (12):2257–2263. DOI: 10.1111/jdv.15171. PMID: 29972712.
Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena GA. Topical finasteride in the treatment of androgenetic alopecia:preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8:189–192. DOI:10.3109/09546639709160517.Corpus ID: 73137922
Piraccini BM, Blume-PeytaviU,Scarci F, et al. On behalf of the Topical Finasteride Study Group Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. JEADV.2022, 36, 286–294. DOI: 10.1111/jdv.17738. PMID: 34634163.
Lee SW, Juhasz M, Mobasher P, Ekelem C, and MesinkovskaNA.A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.J Drugs Dermatol. 2018; 17(4): 457–463. PMID: 29601622. PMCID: PMC6609098
Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10(2):115–9. PMID: 2972662.
Esmat SM, MD, Hegazy RA, Gawdat HI. Low Level Light-Minoxidil 5% Combination versus Either Therapeutic Modality Alone in Management of Female Patterned Hair Loss: A Randomized Controlled Study.LSM.2017; 49:835–843. DOI: 10.1002/lsm.22684. PMID: 28489273.
Olsen E, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. JAAD.2007;57 (5):767–774. DOI: 10.1016/j.jaad.2007.04.012. PMID: 17761356.
Lucky A, Piacquadio D, Ditre C, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. JAAD. 2004; 50(4):541–553. DOI: 10.1016/j.jaad.2003.06.014. PMID: 15034503.
Chitalia J, Dhurat R, Goren A, et al. Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. Dermatol Ther. 2018; 31(6):e12688 DOI: 10.1111/dth.12688. PMID: 30295395.
Shetty V, Goel S. Dermoscopic pre‐ and posttreatment evaluation in patients with androgenetic alopecia on platelet‐rich plasma—A prospective study.J Cosmet Dermatol. 2019;18: 1380–1388. DOI: 10.1111/jocd.12845. PMID: 30556270.
Rakowska A, Slowinska M, Kowalska- Oledzka E, et al. Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology. 2009;1(2):123-30. DOI: 10.4103/0974-7753.58555. PMID: 20927234.
Eudy G and Solomon A. The histopathology of noncicatricial alopecia. Semin Cutan Med Surg. 25(1), 35-40 (2006). DOI: 10.1016/j.sder.2006.01.005. PMID: 16616301.
Karadag Kose O, Gulec A. Clinical evaluation of alopecias using a handheld dermatoscope. JAAD.2012; 67:206–214. DOI: 10.1016/j.jaad.2011.08.019. PMID: 22024772.
Zhang X, Caulloo S, Zhao Y, et al. Female pattern hair loss: clinico-laboratory findings and trichoscopy depending on disease severity. Int J Trichol. 2012; 4: 23–28. DOI: 10.4103/0974-7753.96082. PMID: 22628986.
Rudnicka L, Rakowska A, Olszewska M. Trichoscopy: how it may help the clinician. Dermatol Clin. 2013; 31: 29–41. DOI: 10.1016/j.det.2012.08.011. PMID: 23159174.
Kibar M, Aktan S, Bilgin M. Scalp dermatoscopic findings in androgenetic alopecia and their relations with disease severity. Ann Dermatol. 2014;26(4):478-84. DOI: 10.5021/ad.2014.26.4.478. PMID: 25143677.
Chiramel M, Sharma V, Khandpur S, et al. Relevance of trichoscopy in the differential diagnosis of alopecia: a cross-sectional study from North India. IJDVL. 2016;82(6):651-8. DOI: 10.4103/0378-6323.183636 PMID: 27297280.
Kaur K, Kaur J, Sharma S. Evaluation of trichoscopic findings in androgenetic alopecia and their association with disease severity. Iran J Dermatol.2022; 25: 117-122. DOI: 10.22034/ijd.2021.257541.1273.
Inui S, Nakajima T, Itami S. Scalp dermoscopy of androgenetic alopecia in Asian people. J Dermatol. 2009; 36(2):82-5. DOI: 10.1111/j.1346-8138.2009.00593.x. .PMID: 19284450.
Deloche C,de Lacharrière O, Misciali Cet al. Histological features of peripilar signs associated with androgenic alopecia. Arch Dermatol Res. 2004;295(10), 422-428 . DOI: 10.1007/s00403-003-0447-y. PMID: 14758487.
Ramos L, Santili M, Bezerra F, Ruiz Mde F, Petri V, Patriarca M..Dermoscopic findings in female androgenetic alopecia. An Bras Dermatol. 2012; 87: 691–694 DOI: 10.1590/s0365-05962012000500003. PMID: 23044559.
Ross E, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. JAAD. 2006; 55: 799–806. DOI: 10.1016/j.jaad.2006.04.058. PMID: 17052485.
Hu R, Xu F, Han Y, et al. Trichoscopic findings of androgenetic alopecia and their association with disease severity. J Dermatol. 2015;42(6):602-7. DOI: 10.1111/1346-8138.12857. PMID: 25810236.
Kaliyadan F, Nambiar A, Vijayaraghavan S Androgenetic alopecia: an update.Indian J Dermatol Venereol Leprol. 2013;79(5):613-25. doi: 10.4103/0378-6323.116730.PMID: 23974579.
Davies G, Thornton M, Jenner T, et al. Novel and established potassium channel openers stimulate hair growth in vitro: Implications for their modes of action in hair follicles. J Invest Dermatol.2005;124:686–694. DOI: 10.1111/j.0022-202X.2005.23643.x. PMID: 15816824
El-Garf A, Salah E, Ahmed M. The Use of Trichoscopy to Assess the Efficacy of Topical Minoxidil 2% Solution in Patients with Female Pattern Hair Loss. Zagazig University Medical Journals.2019; 25 ( 5), 782-789. DOI: 10.21608/zumj.
Gupta A, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?.J cosmet dermatol. 2022;21(5):1841-8. DOI: 10.1111/jocd.14895. PMID: 35238144.
Gowda A, Sushmitha K, Chandra K. Comparative study of efficacy of topical minoxidil versus topical minoxidil with finasteride in androgenetic alopecia.Int J Res Dermatol. 2021;7(3):1-5. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20211448
Mohamed A, Elshahid A, Ammar A, Abdel-Dayem H. Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia, comparative study. J Cosmet Dermatol. 2022;21(11):5790-5799. DOI: 10.1111/jocd.15328.PMID: 36039391.
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.JAAD.2011;65:1126-1134. DOI: 10.1016/j.jaad.2010.09.724.PMID: 21700360
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Naglaa Mohamed El Sayed, Eman Hamed Elmorsy, Tarek Mahmoud Hussein, Eman Hassan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
